Upstream Bio, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Upstream Bio increases its IPO size by registering an additional 2,875,000 shares of common stock.
NASDAQ
Upstream Bio, a clinical-stage biotech firm, is set to launch its initial public offering, aiming to raise $190 million to advance its verekitug program targeting severe respiratory and inflammatory diseases.
NASDAQ
Upstream Bio, a clinical-stage biotech firm, has filed an S-1 registration statement for an initial public offering to further develop its treatments for inflammatory diseases, particularly severe respiratory disorders.